Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies
- 448 Downloads
Glutathione peroxidase (GPx-1) is regarded as one of the mammalian cell’s main antioxidant enzymes inactivating hydrogen peroxide and protecting against oxidative stress. Using control, Parkinson’s disease (PD), and dementia with Lewy bodies tissue (DLB) we have shown that GPx-1 is a 21-kD protein under reducing conditions in all tissues examined but is not in high abundance in human brain. Using immunohistochemistry we have mapped the cellular distribution of GPx-1 and have shown it to be in highest levels in microglia and with lower levels in neurons. Only a trace amount was detectable in astrocytes using immunofluorescence and GPx-1 was not detectable in oligodendrocytes. GPx-1 positive microglia were hypertrophied and more abundant in PD and DLB tissues and were seen to be making multiple contacts with neurons. In some cases neurons containing Lewy bodies were surrounded by microglia. Unstructured Lewy bodies were enveloped with a layer of GPx-1 that was partially colocalized with α-synuclein whereas concentric Lewy bodies had discrete deposits of GPx-1 around the periphery which appeared to be involved in the degradation of the Lewy bodies. These results suggest that abnormal α-synuclein as found in Lewy bodies produce hydrogen peroxide and these neurons are capable of directing antioxidant enzymes to regions of oxidative stress. These results also suggest that GPx-1 positive microglia are involved in neuroprotection in PD and DLB and that GPx-1 is an important antioxidant enzyme in neuronal defences.
KeywordsGray Matter Myelin Basic Protein Lewy Body Dementia With Lewy Body Middle Frontal Gyrus
We gratefully acknowledge the excellent assistance of the Flinders University Flinders University Microscopy and Image Analysis Facility and the South Australian Brain Bank. We also acknowledge the excellent technical assistance of Ms. Karen Humphreys and Ms. Christiane Simon. The useful discussions with Mr. James Manavis, Dr. Weiping Gai, and Professor James Temlett are gratefully acknowledged. This work was supported by the Flinders Medical Centre Foundation and a Flinders University Faculty Grant.
- 3.Crack PJ, Taylor JM, Flentjar NJ, de Haan J, Hertzog P, Iannello RC, Kola I (2001) Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. J Neurochem 78:1389–1399. doi: 10.1046/j.1471-4159.2001.00535.x PubMedCrossRefGoogle Scholar
- 5.Deng Y, Lu J, Sivakumar V, Ling EA, Kaur C (2008) Amoeboid microglia in the periventricular white matter induce oligodendrocyte damage through expression of proinflammatory cytokines via MAP kinase signaling pathway hypoxic neonatal rats. Brain Pathol 18:387–400. doi: 10.1111/j.1750-3639.2008.00138.x PubMedCrossRefGoogle Scholar
- 7.Flentjar HJ, Crack PJ, Boyd R, Malin M, de Haan JB, Hertzog KolaI, Iannello R (2002) Mice lacking glutathione peroxidase-1 activity show increased tunel staining and an accelerated inflammatory response in brain following a cold-induced injury. Exp Neurol 177:9–20. doi: 10.1006/exnr.2002.7927 PubMedCrossRefGoogle Scholar
- 14.Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL (2002) Human α-synuclein-harboring familial Parkinson’s disease-linked Ala–53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99:8968–8973. doi: 10.1073/pnas.132197599 PubMedCrossRefGoogle Scholar
- 15.Lindenau J, Noack H, Asayama K, Wolf G (1998) Enhanced cellular glutathione peroxidase immunoreactivity in activated astrocytes and in microglia during excitotoxin induced neurodegeneration. Glia 24:252–256. doi:10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-ZPubMedCrossRefGoogle Scholar
- 17.McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa d, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday g, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier S, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies. Neurology 65:1863–1872. doi: 10.1212/01.wnl.0000187889.17253.b1 PubMedCrossRefGoogle Scholar
- 20.Power JHT, Asad S, Chataway T, Chegini F, Manavis J, Temlett JA, Jensen PH, Blumbergs PC, Gai W (2008) Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer’s disease pathology. Acta Neuropathol 115:611–622. doi: 10.1007/s00401-008-0373-3 PubMedCrossRefGoogle Scholar
- 23.Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Huliman M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller d, Blancato J, Hardy J, Gwinn-Hardy K (2003) α-Synuclein locus triplication causes Parkinson’s disease. Science 302:841. doi: 10.1126/science.1090278 PubMedCrossRefGoogle Scholar
- 27.Tabner BJ, Turnbull S, El-Agnaf OMA, Allsop D (2002) Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic Biol Med 32:1076–1083. doi: 10.1016/S0891-5849(02)00801-8 PubMedCrossRefGoogle Scholar